BioCentury | Oct 1, 2020
Politics, Policy & Law

House committee targets Mallinckrodt, Amgen and Novartis over price increases

...$100 per vial for 50 years until Questcor Pharmaceuticals Inc....
...acquired rights to the drug in 2001. Questcor...
...to $31,000 per vial. Since Mallinckrodt acquired Questcor...
BioCentury | May 25, 2017
Company News

Management tracks

...governance firm CamberView Partners, and previously was EVP of strategic affairs and general counsel at Questcor Pharmaceuticals Inc....
BioCentury | Sep 16, 2016
Company News

Management tracks

...Eldon Mayer as EVP and chief commercial officer. Mayer was SVP of commercial operations at Questcor Pharmaceuticals Inc....
BioCentury | Jan 5, 2015
Finance

2015 Financial Markets Preview: Show me in 2015

...billion takeout of InterMune Inc. by Roche (SIX:ROG; OTCQX:RHHBY); and the $5.7 billion takeout of Questcor Pharmaceuticals Inc....
BioCentury | Sep 1, 2014
Company News

Questcor, Mallinckrodt deal

...Mallinckrodt completed its acquisition of Questcor in a cash and stock deal that values Questcor at...
...Mallinckrodt’s close of $69.61 on Aug. 13, the last trading day before the deal closed. Questcor...
...shareholders received $30 per share in cash and 0.897 Mallinckrodt shares (see BioCentury, April 14). Questcor Pharmaceuticals Inc....
BioCentury | Sep 1, 2014
Company News

Mallinckrodt management update

...Ray Furey as SVP and chief compliance officer, formerly SVP and chief compliance officer of Questcor Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Company News

Novartis, Questcor deal

...of the individual MAAs to transfer to Questcor from Novartis by the end of 2016. Questcor...
...the first 24 amino acids of the adrenocorticotrophic hormone (ACTH). Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Questcor Pharmaceuticals Inc....
BioCentury | May 19, 2014
Company News

Questcor deal

...Questcor said it partnered with an undisclosed private European company to develop melanocortin peptides. Questcor received...
...exclusive, worldwide rights to the undisclosed company's technology and its novel library of melanocortin peptides. Questcor...
...the option to acquire the technology during clinical development. Questcor declined to disclose further details. Questcor Pharmaceuticals Inc....
BioCentury | May 5, 2014
Finance

Pulling off the AZ gambit

...$280-$310M. The Street was expecting $410.4M in 2014 revenues, including a $60M payment from J&J. Questcor Pharmaceuticals Inc....
...increase to expanded usage of autoimmune and inflammatory drug H.P. Acthar Gel repository corticotropin injection. Questcor...
BioCentury | May 5, 2014
Financial News

Questcor financial update

...of July 1. The company, which closed Friday at $83.05, has 61 million shares outstanding. Questcor Pharmaceuticals Inc....
Items per page:
1 - 10 of 253
BioCentury | Oct 1, 2020
Politics, Policy & Law

House committee targets Mallinckrodt, Amgen and Novartis over price increases

...$100 per vial for 50 years until Questcor Pharmaceuticals Inc....
...acquired rights to the drug in 2001. Questcor...
...to $31,000 per vial. Since Mallinckrodt acquired Questcor...
BioCentury | May 25, 2017
Company News

Management tracks

...governance firm CamberView Partners, and previously was EVP of strategic affairs and general counsel at Questcor Pharmaceuticals Inc....
BioCentury | Sep 16, 2016
Company News

Management tracks

...Eldon Mayer as EVP and chief commercial officer. Mayer was SVP of commercial operations at Questcor Pharmaceuticals Inc....
BioCentury | Jan 5, 2015
Finance

2015 Financial Markets Preview: Show me in 2015

...billion takeout of InterMune Inc. by Roche (SIX:ROG; OTCQX:RHHBY); and the $5.7 billion takeout of Questcor Pharmaceuticals Inc....
BioCentury | Sep 1, 2014
Company News

Questcor, Mallinckrodt deal

...Mallinckrodt completed its acquisition of Questcor in a cash and stock deal that values Questcor at...
...Mallinckrodt’s close of $69.61 on Aug. 13, the last trading day before the deal closed. Questcor...
...shareholders received $30 per share in cash and 0.897 Mallinckrodt shares (see BioCentury, April 14). Questcor Pharmaceuticals Inc....
BioCentury | Sep 1, 2014
Company News

Mallinckrodt management update

...Ray Furey as SVP and chief compliance officer, formerly SVP and chief compliance officer of Questcor Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Company News

Novartis, Questcor deal

...of the individual MAAs to transfer to Questcor from Novartis by the end of 2016. Questcor...
...the first 24 amino acids of the adrenocorticotrophic hormone (ACTH). Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Questcor Pharmaceuticals Inc....
BioCentury | May 19, 2014
Company News

Questcor deal

...Questcor said it partnered with an undisclosed private European company to develop melanocortin peptides. Questcor received...
...exclusive, worldwide rights to the undisclosed company's technology and its novel library of melanocortin peptides. Questcor...
...the option to acquire the technology during clinical development. Questcor declined to disclose further details. Questcor Pharmaceuticals Inc....
BioCentury | May 5, 2014
Finance

Pulling off the AZ gambit

...$280-$310M. The Street was expecting $410.4M in 2014 revenues, including a $60M payment from J&J. Questcor Pharmaceuticals Inc....
...increase to expanded usage of autoimmune and inflammatory drug H.P. Acthar Gel repository corticotropin injection. Questcor...
BioCentury | May 5, 2014
Financial News

Questcor financial update

...of July 1. The company, which closed Friday at $83.05, has 61 million shares outstanding. Questcor Pharmaceuticals Inc....
Items per page:
1 - 10 of 253